

## References:

1. Aducanumab (Aduhelm) Prescribing Information. Updated July 2021. Accessed April 5, 2022. [https://www.accessdata.fda.gov/drugsatfda\\_docs/label/2021/761178s003lbl.pdf](https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/761178s003lbl.pdf)
2. Albert MS, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers Dement*. 2011;7(3):270-279.
3. Alzheimer's Association. Alzheimer's Disease Facts and Figures 2021. Accessed August 2021. <https://www.alz.org/media/Documents/alzheimers-facts-and-figures.pdf>
4. Alzheimer's Association. 2021 Alzheimer's disease facts and figures. *Alzheimers Dement*. 2021;17(3):327-406.
5. Atri A. Current and future treatments in Alzheimer's disease. *Semin Neurol*. 2019; 39(2):227–240.
6. Atri A. The Alzheimer's disease clinical spectrum: Diagnosis and management. *Med Clin North Am*. 2019;103(2):263-293.
7. Biogen announces reduced price for ADULHELM® to improve access for patients with early Alzheimer's disease. Accessed May 1, 2022. <https://investors.biogen.com/news-releases/news-release-details/biogen-announces-reduced-price-aduhelmr-improve-access-patients>
8. Breakthrough therapy designation for LECANEMAB (BAN2401), an anti-amyloid beta protofibril antibody for the treatment of Alzheimer's disease. Press release. Eisai, Biogen Inc. website. Accessed August 22, 2021. <https://investors.biogen.com/news-releases/news-release-details/eisai-and-biogen-inc-announce-us-fda-grants-breakthrough-therapy>.
9. CMS finalizes Medicare coverage policy for monoclonal antibodies directed against amyloid for the treatment of Alzheimer's disease. Press release. CMS website. Last updated April 7, 2022. Accessed April 8, 2022. <https://www.cms.gov/newsroom/press-releases/cms-finalizes-medicare-coverage-policy-monoclonal-antibodies-directed-against-amyloid-treatment>
10. Cummings, J, Rabinovici GD, Atri A, et al. Aducanumab appropriate use recommendations update. *J Prevent Alz Dis*. 2022;9:221-230.
11. Cummings J, et al. Appropriate use recommendations. *J Prev Alzheimers Dis*. 2021;8(4):398-410. doi:10.14283/jpad.2021.41
12. Cummings J. New approaches to symptomatic treatments for Alzheimer's disease. *Mol Neurodegener*. 2021;16(1):2. Erratum in: *Mol Neurodegener*. 2021 Apr 1;16(1):21.
13. Day G, et al. Aducanumab use in symptomatic Alzheimer disease evidence in focus: Report of the AAN guidelines subcommittee. *Neurology*. 2022;98(15):619-631.
14. Dickerson B, Atri A. Molecular imaging biomarkers in dementia: Amyloid and tau PET imaging aids evaluation of patients suspected of having Alzheimer disease or other dementias. *Pract Neurol (Fort Wash Pa)*. 2020;19(9):34-45.
15. El-Hayek Y, et al. *J Alzheimers Dis*. 2019;70(2):323-341. de Castro AKA, et al. *International Journal of Computational Intelligence Systems*. 2011. doi: 10.1080/18756891.2011.9727766
16. Ernst J. FDA grants two antibodies breakthrough therapy designation for Alzheimer's disease. Helio. June 24, 2021. Accessed May 1, 2022. <https://www.healio.com/news/neurology/20210624/fda-grants-lecanemab-breakthrough-therapy-designation-for-treatment-of-alzheimers-disease>

17. Haeberlein SB, et al. EMERGE and ENGAGE topline results: Two phase 3 studies to evaluate aducanumab in Ppatients with early Alzheimer's disease. Paper presented at: Clinical Trials on Alzheimer's Disease 2019; San Diego, CA.
18. Hall J, et al. 2021 *Jama Neurol*; CTAD abstract presentation 2021.
19. Hall, et al. Six recurrent amyloid-related imaging abnormality episodes in a patient treated with aducanumab. *JAMA Neurol.* 2022;79(1):87-89.
20. Hampel H, Cummings J, Blennow K, Gao P, Jack CR Jr, Vergallo Aet al. Developing the ATX(N) classification for use across the Alzheimer disease continuum. *Nat Rev Neurol.* 2021;17(9):580-589.
21. Hampel H, et al. The amyloid- $\beta$  pathway in Alzheimer's disease. *Mol Psychiatry.* 2021;26(10):5481-5503.
22. Jack CR, et al. A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers. *Neurology.* 2016;87(5):539-547.
23. Jack CR Jr, et al. NIA-AA research framework: toward a biological definition of Alzheimer's disease. *Alz Dement.* 2018;14(4):535–562.
24. Johnson KA, et al. Update on appropriate use criteria for amyloid PET imaging: dementia experts, mild cognitive impairment, and education. *J Nucl Med.* 2013;54(7):1011-3.
25. Kinney JW, et al. Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement (N Y).* 2018;4:575–590
26. Lilly's donanemab receives U.S. FDA's breakthrough therapy designation for treatment of Alzheimer's disease. Press release. Eli Lilly website. Accessed August 20, 2021.  
<https://investor.lilly.com/news-releases/news-release-details/lillys-donanemab-receives-us-fdas-breakthrough-therapy>
27. Lin P-J, Yang Z, Fillit HM, Cohen JT, Neumann PJ. Unintended benefits: The potential economic impact of addressing risk factors to prevent Alzheimer's disease. *Health Aff (Millwood).* 2014;33(4):547-554.
28. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease. *N Engl J Med.* 2021;384(18):1691-1704.
29. Nobili F, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain<sup>18</sup> F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. *Eur J Neurol.* 2018 Oct;25(10):1201-1217
30. Petersen RC, et al. Practice guideline update summary: Mild cognitive impairment: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology.* 2018;90(3):126-135. doi: 10.1212/WNL.0000000000004826. Epub 2017 Dec 27. Kinney JW, et al. Inflammation as a central mechanism in Alzheimer's disease. *Alzheimers Dement (N Y).* 2018; 4: 575–590;
31. Pospich S, Raunser S. The molecular basis of Alzheimer's plaques. *Science.* 2017;358(6359):45-46.
32. Salloway S, et al. Amyloid-related imaging abnormalities in 2 phase 3 studies evaluating aducanumab in patients with early Alzheimer disease. *JAMA Neurol.* 2022;79(1):13-21.
33. Schneider L. A resurrection of aducanumab for Alzheimer's disease. *Lancet Neurol.* 2020;19(2):111-112.

34. Shaw LM, et al. Appropriate use criteria for lumbar puncture and cerebrospinal fluid testing in the diagnosis of Alzheimer's disease. *Alzheimer's & Dementia*. 2018;14(11):1505-1521.
35. Therapeutics: Lecanemab. Alzforum website. Accessed August 22, 2021.<https://www.alzforum.org/therapeutics/lecanemab>.
36. Whittington MD, et al. Cost-effectiveness and value-based pricing of aducanumab for patients with early Alzheimer disease. *Neurology*. 2022;98(9)e968-e977.